NAD+ × 24peptides.com — lab test, April 2026
This lab doesn't publish a public lookup, so we can't confirm the certificate against the lab's own record. The document was reviewed before publication, but it rests on our review alone.
What portal verification means →Test results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 1000 mg · Lab measured 1106 mg
111% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 276.5 mg using the measured mass, against 250 mg on the label — 11% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
| Report number | GF-NAD1000-B242 |
|---|---|
| Portal lookup | Lab has no portalThis laboratory publishes no public lookup, so the report cannot be confirmed independently. |
| PDF vs portal | liquilabs's portal shows validity only |
| Weight | Counts as one lab test |
Independent HPLC purity analysis of NAD+ from 24peptides.com, performed by liquilabs on April 20, 2026. Reported purity: 99%. Net content: 1106 mg against 1000 mg labeled (111% of label). Tested content exceeds the labeled amount by 11%. Endotoxins: < 0.001. Batch GF-NAD1000-B242. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of NAD+ from 24peptides.com
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| GF-NAD1000-B241 | 16 Feb 2026 | liquilabs | 99.1% | 95% | Lab has no portal |
| GF-NAD500-B241 | 28 Jan 2026 | liquilabs | 99.8% | 96% | Lab has no portal |
| GF082025017 | 12 Sept 2025 | liquilabs | 99.4% | 96% | Lab has no portal |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion